“Silence” The noise of food in our head

After several years using semaglutida drugs (such as Ozempic either Wegovy) For weight loss, we have gradually discovering how they exercise this function. These medications, initially developed as diabetes treatment, emulate an important hormone related to the digestive process. But there are still more details that we continue discovering.

Silence the noise. A study He has found indications that Ozempic and the rest of the drug -based drugs are able to silence the “noise of the food.” This means that treatment is able to reduce obsessive and intrusive thoughts related to food and eat.

Explaining operation. Biochemical mechanisms behind the effects of Semaglutida They were already known. This compound is an agonist of the GLP-1 receptors (peptide similar to glucagon 1), that is, they act as a kind of Analogue of this hormonemaking our body think that we are segregating it.

This hormone fulfills two functions, each related to one of the clinical uses of this drug. The hormone is secreted when we eat and transmits information to the pancreas so that it begins to segregate insulin. That is why treatment is useful for glycemic control in patients with type 2 diabetes.

The second hormone function is fulfilled in the brain, and that is that the LPG-1 is responsible for notifying the brain that we have eaten in order to generate the feeling of satiety. This would be at least one of the fundamentals behind the use of semaglutida as a formula to lose weight.

Expanding our knowledge. The study was conducted by researchers from Novo Nordiskthe Danish pharmacist responsible for developing the semaglutida and therefore of the manufacture of medications based on the formula such as Ozempic and Wegovy and an external market for market research.

The analysis was based on a survey of 550 participants, most women and with an average age of 53 years, all users of weight loss treatment. Most of the participants indicated having consumed psemaglutida for at least four months, and also a large majority indicated an initial weight of at least 92 kg at the beginning of the treatment.

Four times less. According to Indicates the responsible team From the new study, the proportion of participants who “experienced constant thoughts about food” went from 62% to 16% throughout the study. The proportion of those who considered that “they spent too long thinking about food” went from 63% to 15%.

According to the team responsible for the study, the “uncontrollable thoughts on food” also descended, moving from a 53% prevalence to one of 15%. The portion of participants also descended that they considered that thoughts on food distracted them from day -to -day activities, from 47% to 15%.

The investigation has been presented at the annual EASD meeting (European Association for the Study of Diabetes), In Vienna.

Placebo effect? There are some details that suggest caution when interpreting the results. The first is that we are faced with a survey and not before an experiment with a control group and randomized allocation of the participants between control group and the experimental group. This implies that we cannot rule out that what is observed is simply due to placebo effect or some other form of autosugestion.

In the Press note It is pointed out that three of the researchers responsible for the new study are also employees of Pharmaceuticals Novo Nordisk. This does not necessarily remain validity to the study, but transparency is an indispensable requirement in this type of work. The study, for now, has not gone through the revision process of peers of those who are published in scientific journals.

In Xataka | Novo Nordisk has found the formula to recover the profitability of Ozempic: fire 9,000 employees

Image | Chemist4u / Xataka with Gemini